Metamizol for the Treatment of Neoplastic Chronic Pain

Boehringer Ingelheim

Status and phase: Terminated; Phase 4

Conditions: Pain

Treatments: Drug: Metamizole placebo; Drug: Metamizole; Drug: Diclofenac; Drug: Diclofenac placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT02181920

1093.14

Details and patient eligibility

About

Study to evaluate the efficacy of metamizole in reducing morphine requirements in patients with moderate to severe chronic cancer pain in comparison to administration of placebo or diclofenac.

Enrollment: 6 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hospitalized patients with neoplastic chronic pain requiring morphine treatment

Exclusion criteria

• Karnofsky index less than 30%

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

6 participants in 4 patient groups

Metamizole - Diclofenac

Experimental group

Description:

metamizole followed by diclofenac

Treatment:

Drug: Metamizole placebo

Drug: Diclofenac placebo

Drug: Diclofenac

Drug: Metamizole

Diclofenac - Metamizole

Experimental group

Description:

diclofenac followed by metamizole

Treatment:

Drug: Metamizole placebo

Drug: Diclofenac placebo

Drug: Diclofenac

Drug: Metamizole

Metamizole - Placebo

Experimental group

Description:

metamizole followed by placebo

Treatment:

Drug: Metamizole placebo

Drug: Diclofenac placebo

Drug: Metamizole

Placebo - Metamizole

Experimental group

Description:

placebo followed by metamizole

Treatment:

Drug: Metamizole placebo

Drug: Diclofenac placebo

Drug: Metamizole